Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 39

Related Articles by Review for PubMed (Select 21911885)

1.

Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.

Ridruejo E, Solano A, Marciano S, Galdame O, Adrover R, Cocozzella D, Delettieres D, Martínez A, Gadano A, Mandó OG, Silva MO.

Ann Hepatol. 2011 Oct-Dec;10(4):452-7.

2.

Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis.

Bota S, Sporea I, Şirli R, Neghină AM, Popescu A, Străin M.

Clin Drug Investig. 2013 May;33(5):325-31. doi: 10.1007/s40261-013-0074-0. Review.

PMID:
23532802
3.

Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients.

Mangia A, Mottola L, Santoro R.

World J Gastroenterol. 2013 Dec 21;19(47):8924-8. doi: 10.3748/wjg.v19.i47.8924. Review.

4.

Effect of spleen operation on antiviral treatment in hepatitis C virus-related cirrhotic patients.

Feng B, Zhang W, Luo BF, Song GJ, Wang J, Jin Q, Qin H, Wei L.

World J Gastroenterol. 2014 Nov 7;20(41):15387-97. doi: 10.3748/wjg.v20.i41.15387. Review.

5.

The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C.

Bellanti F, Vendemiale G, Altomare E, Serviddio G.

Clin Dev Immunol. 2012;2012:849373. doi: 10.1155/2012/849373. Epub 2012 Aug 27. Review.

6.

Is there still a role for PEG IFN+RBV therapy in patients with HCV genotype 1?

Serfaty L.

Liver Int. 2014 Feb;34 Suppl 1:11-2. doi: 10.1111/liv.12407. Review.

PMID:
24373072
7.

Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis.

Manzano-Robleda Mdel C, Ornelas-Arroyo V, Barrientos-Gutiérrez T, Méndez-Sánchez N, Uribe M, Chávez-Tapia NC.

Ann Hepatol. 2015 Jan-Feb;14(1):46-57. Review.

8.

Host factors determining the efficacy of hepatitis C treatment.

Chuang WL, Yu ML.

J Gastroenterol. 2013 Jan;48(1):22-30. doi: 10.1007/s00535-012-0669-x. Epub 2012 Oct 27. Review.

9.

Current management and perspectives for HCV recurrence after liver transplantation.

Coilly A, Roche B, Samuel D.

Liver Int. 2013 Feb;33 Suppl 1:56-62. doi: 10.1111/liv.12062. Review.

PMID:
23286847
10.

Efficacy of daclatasvir in hepatitis C virus.

Izumi N.

Expert Rev Anti Infect Ther. 2014 Sep;12(9):1025-31. doi: 10.1586/14787210.2014.942282. Epub 2014 Jul 25. Review.

PMID:
25059552
11.

Review article: genetic factors that modify the outcome of viral hepatitis.

Stättermayer AF, Scherzer T, Beinhardt S, Rutter K, Hofer H, Ferenci P.

Aliment Pharmacol Ther. 2014 May;39(10):1059-70. doi: 10.1111/apt.12717. Epub 2014 Mar 24. Review.

PMID:
24654629
12.

How to optimize HCV therapy in genotype 1 patients: predictors of response.

Petta S, Craxì A.

Liver Int. 2013 Feb;33 Suppl 1:23-9. doi: 10.1111/liv.12053. Review.

PMID:
23286842
13.

Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: optimizing use of peginterferon alfa.

Liu CH, Kao JH.

Int J Nanomedicine. 2014 Apr 25;9:2051-67. doi: 10.2147/IJN.S41822. eCollection 2014. Review.

14.

Management of hepatitis C virus infection: the basics.

Naggie S.

Top Antivir Med. 2012 Dec;20(5):154-61. Review.

15.

HCV NS5A inhibitors in development.

Suk-Fong Lok A.

Clin Liver Dis. 2013 Feb;17(1):111-21. doi: 10.1016/j.cld.2012.09.006. Review.

PMID:
23177287
16.

Individualized therapy for hepatitis C infection: focus on the interleukin-28B polymorphism in directing therapy.

Lee TH, Tillmann HL, Patel K.

Mol Diagn Ther. 2014 Feb;18(1):25-38. Review.

PMID:
24022240
17.

Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?

Shiffman ML, Benhamou Y.

Liver Int. 2013 Feb;33 Suppl 1:105-10. doi: 10.1111/liv.12066. Review.

PMID:
23286853
18.

Genomic determinants of hepatitis C virus antiviral therapy outcomes: toward individualized treatment.

Venegas M, Brahm J, Villanueva RA.

Ann Hepatol. 2012 Nov-Dec;11(6):827-37. Review.

19.

IL28B in the era of direct-acting antivirals for hepatitis C.

Muir AJ.

J Clin Gastroenterol. 2013 Mar;47(3):222-7. doi: 10.1097/MCG.0b013e3182680221. Review.

PMID:
23328301
20.

Hepatitis C virus and interferon type III (interferon-λ3/interleukin-28B and interferon-λ4): genetic basis of susceptibility to infection and response to antiviral treatment.

Riva E, Scagnolari C, Turriziani O, Antonelli G.

Clin Microbiol Infect. 2014 Dec;20(12):1237-45. doi: 10.1111/1469-0691.12797. Epub 2014 Dec 12. Review.

PMID:
25273834
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk